Eiry Roberts - Neurocrine Biosciences Chief Medical Officer
| NBIX Stock | USD 132.54 0.69 0.52% |
Executive
Ms. Eiry W. Roberts, M.D. is Chief Medical Officer of the Company. Dr. Roberts has over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic areas, including neuroscience, inflammation, oncology and metabolic diseases. She joins Neurocrine from Eli Lilly and Company where she held various positions during her tenure, including Vice President, Clinical Pharmacology and Vice President of RD, BioMedicines Business Unit. Dr. Roberts was the Chair of the Medical Review Committee, where she was responsible for review and approval of all the integrated clinical plans for molecules in the Lilly portfolio. She was also a member of Lilly Corporationrationrate Portfolio Management Committee and Lilly Ventures Steering Committee. Dr. Roberts was accountable for early clinical development programs across all therapeutic areas within Lilly, as well as registration for new chemical entities and biproducts in Phase III development. During her time at Lilly, Dr. Roberts established a new therapeutic area, which resulted in the development of five potential novel medicines from Phase I through to approval, with two of them successfully receiving regulatory approval. Dr. Roberts also has extensive leadership and business development experience, including the management of strategic alliances, business partnerships and VC collaborations. since 2018.
| Age | 54 |
| Tenure | 6 years |
| Address | 12780 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 617 7600 |
| Web | https://www.neurocrine.com |
Eiry Roberts Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eiry Roberts against Neurocrine Biosciences stock is an integral part of due diligence when investing in Neurocrine Biosciences. Eiry Roberts insider activity provides valuable insight into whether Neurocrine Biosciences is net buyers or sellers over its current business cycle. Note, Neurocrine Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neurocrine Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eiry Roberts over three months ago Sale by Eiry Roberts of 6978 shares of Neurocrine Biosciences | ||
Eiry Roberts over six months ago Sale by Eiry Roberts of 3198 shares of Neurocrine Biosciences | ||
Eiry Roberts over a year ago Sale by Eiry Roberts of 1457 shares of Neurocrine Biosciences |
Neurocrine Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Craig MD | Alkermes Plc | 56 | |
| Richard Malamut | Collegium Pharmaceutical | N/A | |
| Willie MD | Intracellular Th | N/A | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Lisa Price | Deciphera Pharmaceuticals LLC | N/A | |
| Max Reinhardt | Pacira Pharmaceuticals | 53 | |
| Robert Weiland | Pacira Pharmaceuticals | 57 | |
| Blair Jackson | Alkermes Plc | 51 | |
| Helen Peters | Evotec SE ADR | 69 | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Scott Eston | Evotec SE ADR | 60 | |
| Gabriele Hansen | Evotec SE ADR | N/A | |
| Kevin Brodbeck | Deciphera Pharmaceuticals LLC | N/A | |
| Margarida Duarte | Deciphera Pharmaceuticals LLC | N/A | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Sandra Coombs | Alkermes Plc | N/A | |
| Christopher Morl | Deciphera Pharmaceuticals LLC | 59 | |
| Melissa Forst | Deciphera Pharmaceuticals LLC | N/A | |
| MBA MPA | Evotec SE ADR | 56 | |
| Volker Braun | Evotec SE ADR | N/A | |
| Kirsten Long | Evotec SE ADR | N/A | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 |
Neurocrine Biosciences Leadership Team
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Mollica, Independent Director | ||
| George Morrow, Director | ||
| Matthew Abernethy, Chief Officer | ||
| Richard Pops, Independent Director | ||
| Eric Benevich, Chief Commercial Officer | ||
| William Rastetter, Independent Chairman of the Board | ||
| Darin Lippoldt, Chief Legal Officer | ||
| Alfred Sandrock, Director | ||
| Jude Onyia, Chief Officer | ||
| Matt Abernethy, CFO | ||
| Navjot Rai, IR Contact Officer | ||
| Darin Esq, Chief Secretary | ||
| Bill Aurora, Vice President - Medical Affairs | ||
| David Boyer, Chief Officer | ||
| Christopher OBrien, Chief Medical Officer | ||
| Stephen Sherwin, Independent Director | ||
| Julie Cooke, Chief People Officer | ||
| DavidAlexandre Gros, President COO | ||
| Eiry Roberts, Chief Medical Officer | ||
| Corinne Nevinny, Independent Director | ||
| Dimitri Grigoriadis, Chief Research Officer | ||
| Haig Bozigian, Chief Devel. Officer | ||
| Kyle Gano, Chief Business Development Officer | ||
| Gary Lyons, Independent Director | ||
| Timothy Coughlin, CFO, Principal Accounting Officer and VP | ||
| Jane Sorensen, Investor Relations Officer | ||
| Malcolm LloydSmith, Chief Regulatory Officer | ||
| Eiry MD, Chief Officer | ||
| Kevin Gorman, CEO and President and Director | ||
| Ingrid Delaet, Chief Officer |
Neurocrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurocrine Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 12.62 B | ||||
| Shares Outstanding | 100.58 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 94.41 % | ||||
| Number Of Shares Shorted | 2.43 M | ||||
| Price To Earning | 202.90 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.47 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.